Indian Scientist Dr. Hidayat Bukhari Achieves Dual Recognition at ASCO 2025 for Pioneering AI-Powered Cancer Diagnostics
You are Here: Tweet, Like, Share, Comment, Subscribe…be the Voice of Free Press!
By Samreen Tak, Copy Edited By Adam Rizvi, The India Observer, TIO: June 11, 2025 | New Delhi, India — In a significant moment for global cancer research and the future of precision oncology, Dr.Hidayat Bukhari, a clinical researcher from Shri Venkateshwara University in India, has received rare and commendable recognition at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting—the world’s most prestigious oncology forum. Dr. Bukhari’s two research abstracts, focused on transforming conventional histopathology through artificial intelligence, were selected for publication, marking a milestone not only in his career but also for India’s growing role in computational medicine.
The studies represent a bold and elegant fusion of artificial intelligence, pathology, and molecular oncology, targeting one of the most treatment-resistant cancers in the world: stomach adenocarcinoma. By using deep learning algorithms to decode patterns within standard diagnostic slides, Dr. Bukhari’s work opens a new frontier in non-invasive, scalable, and interpretable cancer diagnostics—with implications that reach far beyond the lab.
Also Read, Tweet & Share: Journey from Aligarh to Moon- Chandrayaan-3
A Vision for Interpretable, Accessible AI in Oncology
Unlike many AI tools in medicine that are limited by their “black-box” nature, Dr. Bukhari’s models are designed to be clinically transparent and biologically meaningful. The central innovation lies in the extraction of human-interpretable image features (HIFs) from routine H&E-stained pathology slides. These features—such as immune cell proximity to tumor tissue, or the ratio of fibroblasts to stroma—mirror the underlying tumor biology with surprising accuracy.
Leveraging data from The Cancer Genome Atlas (TCGA), these image-derived insights were correlated with gene expression signatures and patient survival outcomes, revealing patterns that have the potential to transform treatment selection and early risk assessment.
“What we’ve shown is that AI can be trained to think like a pathologist, but at scale and with molecular precision,” said Dr. Bukhari. “The advantage is that these insights come from standard pathology slides that every hospital already generates—making it globally scalable, not just a privilege of wealthy institutions.”
Also Read, Tweet & Share: “Every Drop Counts” : An evening with “The Water Man of India”
Two Landmark Studies with a Common Goal: Personalization
In the first study, titled “Predicting therapeutic response in stomach adenocarcinoma by integrating H&E and RNA-seq using deep learning” (ASCO Abstract #e16088), the research team discovered that lower expression of the gene LMNB1 is strongly associated with therapeutic resistance. The finding gains further clinical power when matched with a specific HIF: the density of cancer cells within the immune zone of lymphocytes. Patients whose tumors exhibit high LMNB1 expression and immune cell engagement were significantly more likely to benefit from immune checkpoint inhibitors.
The second study, “Linking gene expression to tumor microenvironment using H&E features in stomach adenocarcinoma” (ASCO Abstract #e14635), focused on identifying biological signatures of poor prognosis. Four genes—ABCA6, ABCA8, ADAM33, and ADAMTS10—were found to be significantly correlated with high-density stromal and macrophage environments, characteristics known to suppress immune response and foster aggressive disease. These markers, when combined with AI-generated HIFs, can help clinicians identify high-risk patients before clinical deterioration begins.
“These two studies work in tandem,” Dr. Bukhari explained. “One identifies patients who are likely to respond well to current therapies. The other flags patients who may need alternate or intensified strategies from the very beginning.”
Also Read, Tweet & Share: Event for Shri Thanedar hosted by US India Security Council in Boston
A Global Leap for Low-Resource Precision Medicine
Perhaps the most compelling dimension of Dr. Bukhari’s research is its radical accessibility. Precision medicine has long been criticized for being geographically and economically exclusive—relying on expensive genomic testing platforms often unavailable in lower- and middle-income countries. Dr. Bukhari’s AI-driven methodology uses no advanced lab equipment or genomic assays, relying solely on existing pathology infrastructure and public data to derive insights that rival, and sometimes surpass, molecular testing.
In an era when equitable access to cancer diagnostics is a global priority, this approach could democratize precision oncology, offering a model that rural hospitals in India, public clinics in Africa, and teaching institutions in South America could all deploy without massive investment.
International Recognition and Future Outlook
The American Society of Clinical Oncology (ASCO) is the gold standard of cancer science conferences, and having two studies accepted for publication at its annual meeting is a rare distinction—especially for researchers working outside of North America and Europe. It signals not just academic rigor, but real-world clinical potential.
“ASCO recognition validates the translational strength of our work,” said Dr. Bukhari. “It tells us we’re building something that can move out of the lab and into the clinic, where it matters most.”
Looking forward, Dr. Bukhari and his collaborators are planning multi-center validation studies across Indian and international hospitals. Discussions are also underway with digital pathology platforms and health technology firms for integration into clinical decision support systems. Additionally, the team is exploring the use of similar AI-HIF frameworks in lung, pancreatic, and colorectal cancers.
Also Read, Tweet & Share: Sir Syed Global Scholar Award(Previously Sir Syed Emerging Scholar Award)
A New Chapter for Computational Oncology in India
Dr. Bukhari’s achievement is not just personal—it’s symbolic. It reflects the arrival of a new generation of Indian researchers who are not only contributing to global science but shaping its direction. In fields as data-heavy and infrastructure-driven as oncology, such breakthroughs remind the world that clinical ingenuity, when paired with AI, can transcend borders and budgets.
As healthcare systems everywhere seek to modernize cancer diagnostics while keeping costs under control, Dr. Hidayat Bukhari’s work may well serve as a blueprint for the future—a future where every slide becomes a story, and every pixel, a possibility.
Curated By Humra Kidwai
Articles written by contributors have different viewpoints. The views expressed in the articles are the author’s own and not necessarily supported by TIO, The India Observer its affiliates, staff, or the management. Our Articles can be reproduced, with the following conditions, (1) No alteration to the content, (2) Visible, and full credit is given to the Author & Editor. (3) Citing, The India Observer, TIO. In the case of online or electronic media, a link to the original article must be given. Rules are strictly enforced. Any questions, email the Editor at: Mediaiss@gmail.com Or TheIndiaObserver@gmail.com
Source:
Photo:
